Joint Walsall Formulary
Walsall Clinical Commissioning Group
Walsall Healthcare NHS Trust
Walsall Clinical Commissioning Group
Walsall Healthcare NHS Trust
2 Cardiovascular system
02-12 Ezetimibe
| Ezetimibe Ezetrol® |
|
Formulary
|
 NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
|
Links
-
- NICE Cardiovascular disease prevention pathway.
- NICE CG127 Hypertension in adults: diagnosis and management
- NICE CG181 - Cardiovascular disease: risk assessment and reduction, including lipid modification
- NICE Guidance - CG107 Hypertension in pregnancy: diagnosis and management
- NICE Guidance - CG108 Chronic heart failure in adults: management
- NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
- NICE TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- Walsall Guidance - ACUTE ST ELEVATION MYOCARDIAL INFARCTION (STEMI) - Under Review
- Walsall Guidance - Pathway for the use of PCSK9 Inhibitors in secondary prevention of cardiovascular disease